Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006

Medical Journal of Australia

Volumn 185, Issue 10, 2006, Pages 549-556

  Krum, Henry ^a   Jelinek, Michael V ^b,c   Stewart, Simon ^d,e   Sindone, Andrew ^f,g   Atherton, John J ^h,i   Hawkes, Anna L ^d   Amerena, John ^j   Beltrame, John ^j   Burrell, Louise ^j   Campbell, Duncan ^j   Davidson, Patricia ^j   DePasquale, Carmine ^j   Doughty, Rob ^j   Esmore, Donald ^j   Feneley, Michael ^j   Galbraith, Andrew ^j   Gilbert, Richard ^j   Goble, Alan ^j   Hare, David ^j   Horowitz, John ^j   Kalman, John ^j   Kaye, David ^j   Keogh, Ann ^j   Larbalestier, Robert ^j   Leitch, James ^j   McDonald, Peter ^j   Marwick, Tom ^j   McGuire, Mark ^j   Meyers, Deborah ^j   Mottram, Phil ^j   Pollock, Carol ^j   Walsh, Warren ^j   more..

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f UNIVERSITY OF WESTERN SYDNEY   (Australia)

^g Department of Microbiology and Infectious Diseases   (Australia)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HAEMOPHILUS INFLUENZAE VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; METFORMIN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PNEUMOCOCCUS VACCINE; SILDENAFIL; SODIUM CHLORIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VERAPAMIL;

AGE; ALCOHOL WITHDRAWAL; ANAMNESIS; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; AUSTRALIA; BED REST; BODY WEIGHT; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL FEATURE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONSULTATION; DEFIBRILLATION; DIAGNOSTIC VALUE; DIETARY FIBER; DISEASE COURSE; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DYSPNEA; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EDEMA; ELDERLY CARE; FATIGUE; FLUID INTAKE; GENERAL PRACTITIONER; HAEMOPHILUS INFLUENZAE; HEART ANEURYSMECTOMY; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE FUNCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; HYPOTENSION; INFLUENZA; ISCHEMIC HEART DISEASE; LOW FAT DIET; MITRAL VALVE REPLACEMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; POSITIVE END EXPIRATORY PRESSURE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; QUALITY OF LIFE; SLEEP APNEA SYNDROME; SMOKING CESSATION; SODIUM RESTRICTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STRESS ECHOCARDIOGRAPHY; SURVIVAL RATE; SYMPTOM; THORAX RADIOGRAPHY; THYROID FUNCTION TEST; TRAVEL; WEIGHT REDUCTION;

EID: 33751416414     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00690.x     Document Type: Article

References (91)

1. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J 2003;5:I3-I113.
2. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-1353.
3. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
4. Australian Institute of Health and Welfare and the National Heart Foundation of Australia. Heart, stroke and vascular diseases-Australian facts 2004. Canberra: National Centre for Monitoring Cardiovascular Disease, 2004:140.
5. Abhayaratna WP, Smith WT, Becker NG, et al. Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study. Med J Aust 2006;184:151-154.
6. Clark RA, McLennan S, Dawson A, et al. Uncovering a hidden epidemic: a study of the current burden of heart failure in Australia. Heart Lung Circ 2004;13:266-273.
7. Krum H, Tonkin AM, Currie R, et al. Chronic heart failure in Australian general practice: the Cardiac Awareness Survey And Evaluation (CASE) study. Med J Aust 2001;174:439-444.
8. Access Economics. The shifting burden of cardiovascular disease in Australia. Canberra: Access Economics Pty Ltd and the National Heart Foundation of Australia, May 2005.
9. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2397.
10. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or non-ischemic dilated cardiomyopathy. Am J Cardiol 1990;66:1348-1354.
11. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (non-fulminant) myocarditis. N Engl J Med 2000;342:690-695.
12. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in children and adolescents. Canberra: NHMRC, 2003.
13. Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992;85:1364-1373.
14. Chati Z, Zannad F, Jeandel C, et al. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate muscle metabolism abnormalities in chronic heart failure. Am Heart J 1996;131:560-566.
15. Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise training and activity restriction in 6-minute walking test performance in patients with chronic heart failure. Am Heart J 1997;133:447-453.
16. Sinoway LI. Effect of conditioning and deconditioning stimuli on metabolically determined blood flow in humans and implications for congestive heart failure. Am J Cardiol 1988;62:45E-48E.
17. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-1195.
18. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999;159:257-261.
19. Naughton MT. Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Thorax 1998;53:S37-S40.
20. McDonald CD, Burch GE, Walsh JJ. Prolonged bed rest in the treatment of idiopathic cardiomyopathy. Am J Med 1972;52:41-50.
21. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-735.
22. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
23. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677.
24. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
25. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-412.
26. Dahlof B, Lindholm JH, Hansson L, et al. Morbidity and mortality in the Swedish trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338: 1281-1285.
27. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research group. JAMA 1997;278:212-216.
28. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.
29. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000;356:366-372.
30. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-365.
31. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 145-153.
32. Kjekshus J, Pederson TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;2:249-254.
33. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
34. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist, felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalaprl: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856-863.
35. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325:293-302.
36. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
37. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J 1998;19:481-489.
38. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.
39. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
40. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT HF). Lancet 1999;353:2001-2007.
41. Packer M, Coates AJ, Fowler MB, et al, for the Carvedilol Prospective Randomised Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the survival of patients with severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
42. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
43. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
44. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
45. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
46. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative study. N Engl J Med 1986;314:1547-1552.
47. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on survival. Evaluation Study Group. N Engl J Med 1996;335:1107-1114.
48. Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000;2:209-212.
49. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med 2000;160:777-784.
50. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000;133:1-9.
51. Keteyian SJ, Brawner CA, Schairer JR, et al. Exercise training in patients with heart failure: a randomised, controlled trial. Ann Intern Med 1996;124:1051-1057.
52. Packer M, Carver JR, Rodeheffer RJ, et al, for the PROMISE Study Reseach Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
53. Hampton JR, Van Veldhuisen DJ, Kleber FX, et al, for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971-977.
54. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
55. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
56. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-880.
57. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
58. Dor V, Sabatier M, Di Donato M, et al. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998;116: 50-59.
59. Dreyfus G, Mihealainu S. The Batista procedure. Heart 2001;85:1-2.
60. Raman JS, Power JM, Buxton B, et al. Ventricular containment as an adjunctive procedure in ischaemic cardiomyopathy: early results. Ann Thorac Surg 2000;70: 1124-1126.
61. Jaski BE, Lingle RJ, Reardon LC, Dembitsky WP. Left ventricular assist device as a bridge to patient and myocardial recovery. Prog Cardiovasc Dis 2000;43:5-18.
62. Rose EA, Gelijns C, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435-1443.
63. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 1998;115:381-388.
64. Dabol R, Edwards NM. Cardiac transplantation and other therapeutic options in the treatment of end-stage heart disease. Compr Ther 2000;26:109-113.
65. Pagano D, Bonser RS, Camici PG. Myocardial revascularization for the treatment of post-ischemic heart failure. Curr Opin Cardiol 1999;14:506-509.
66. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151-1158.
67. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
68. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
69. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-1513.
70. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
71. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237.
72. Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000;160: 2645-2650.
73. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-146.
74. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146: 848-853.
75. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10:101-112.
76. Rich MW. Heart failure disease management: a critical review. J Card Fail 1999;5: 64-75.
77. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-384.
78. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810-819.
79. Phillips CO, Wright SM, Ker DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004;291:1358-1367.
80. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomized controlled study. Lancet 1999; 354:1077-1083.
81. Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation 2002;105:2861-2866.
82. Flather MD, Yusuf S, Kober L, et al. Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-1581.
83. Stewart S, Blue LE. Specialist nurse intervention in chronic heart failure: from research to practice. London: BMJ Books, 2004.
84. NSW Department of Health. Chronic care program 2000-2003: strengthening capacity for chronic care in the NSW health system. Clinical Services Framework for heart failure. Overview of the framework and its standards. Volume 1. Sydney: NSW Health, 2003.
85. Hinton JM. The physical and mental distress of dying. Q J Med 1963;32:1-21.
86. Gibbs LM, Addington-Hall J, Gibbs SJ. Dying from heart failure: lessons from palliative care. BMJ 1998;317:961-962.
87. Stewart A, Greenfield S, Hays RD, et al. Functional status and well being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;262:907-913.
88. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Failure 2001;3: 315-322.
89. Goodlin SJ, Jette AM, Lynn J, Wasson JH. Community physicians describe management issues for patients expected to live less than twelve months. J Palliat Care 1998;14:30-35.
90. Alla F, Briancon S, Guillemin F, et al. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Fail 2002;4:337-343.
91. Stewart S, McMurray JJ. Palliative care for heart failure. BMJ 2002;325:915-916.